Steminent Biotherapeutics Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	-	205.4	451.86	153.43	230.56	40.81
Short-Term Investments	-	11.6	-	-	-	-
Cash & Short-Term Investments	-	217	451.86	153.43	230.56	40.81
Cash Growth	-	-51.98%	194.50%	-33.45%	464.90%	-
Other Receivables	-	0.94	0.84	0.33	0.78	0.26
Receivables	-	0.94	0.84	0.33	0.78	0.26
Inventory	-	12	7.67	3.48	10.4	10.61
Prepaid Expenses	-	-	-	-	1.14	2.01
Other Current Assets	381.92	5.82	6.09	3.91	-	-
Total Current Assets	381.92	235.76	466.46	161.15	242.88	53.69
Property, Plant & Equipment	98.86	168.18	83.16	58.87	22.8	33.52
Other Intangible Assets	-	2.39	0.51	0.32	0.16	0.17
Other Long-Term Assets	86.01	30.34	43.74	15.31	13.66	12.82
Total Assets	566.78	436.66	593.88	235.65	279.5	100.18
Accounts Payable	-	2.54	2.15	1.93	0.65	0.86
Accrued Expenses	-	11.44	13.81	10.11	10.01	7.59
Current Portion of Leases	-	13.68	13.15	7.17	7.9	7.63
Current Unearned Revenue	-	-	-	0.46	1.09	0.08
Other Current Liabilities	34.55	4.06	9.55	4.46	2.85	2.35
Total Current Liabilities	34.55	31.73	38.66	24.12	22.5	18.5
Long-Term Debt	-	-	-	-	-	75.5
Long-Term Leases	-	50.09	62.23	48	11.27	19.17
Long-Term Deferred Tax Liabilities	-	0.15	-	-	-	-
Other Long-Term Liabilities	63.79	-	-	-	1.46	-
Total Liabilities	98.33	81.97	100.89	72.11	35.23	113.17
Common Stock	663.08	560.45	557.95	444.94	444.94	299.72
Additional Paid-In Capital	736.38	581.43	580.17	239.16	239.16	3.84
Retained Earnings	-933.45	-814.27	-655.53	-526.3	-440.82	-316.62
Comprehensive Income & Other	2.44	27.09	10.39	5.74	0.99	0.07
Shareholders' Equity	468.45	354.7	492.99	163.54	244.27	-12.99
Total Liabilities & Equity	566.78	436.66	593.88	235.65	279.5	100.18
Total Debt	-	63.78	75.38	55.16	19.17	102.3
Net Cash (Debt)	-	153.23	376.48	98.27	211.39	-61.48
Net Cash Growth	-	-59.30%	283.12%	-53.51%	-	-
Net Cash Per Share	-	2.74	7.77	2.21	6.00	-2.05
Filing Date Shares Outstanding	56.24	56.05	55.8	44.49	44.49	29.97
Total Common Shares Outstanding	56.24	56.05	55.8	44.49	44.49	29.97
Working Capital	347.37	204.03	427.8	137.03	220.38	35.18
Book Value Per Share	8.33	6.33	8.84	3.68	5.49	-0.43
Tangible Book Value	468.45	352.31	492.47	163.22	244.11	-13.15
Tangible Book Value Per Share	8.33	6.29	8.83	3.67	5.49	-0.44
Machinery	-	99.07	42.81	34.07	32.36	33.22
Leasehold Improvements	-	79.08	41.5	41.05	40.82	40.82

Source: S&P Global Market Intelligence. Standard template. Financial Sources.